Ilico Genetics

Bethlehem, United States Founded: 2020 • Age: 6 yrs
Developer of diagostic test for detection of gastric cancer

About Ilico Genetics

Ilico Genetics is a Healthcare company based in Bethlehem (United States) founded in 2020 by Fernando Alarcon Hardy, Alejandro Corvalan, and Maria Maturana. Developer of diagostic test for detection of gastric cancer. Ilico Genetics has raised $457.74 thousand across 1 funding round. Its chief executive, as recorded, is Fernando Alarcon Hardy. Ilico Genetics offers products and services including Stomach Cancer Screening Test. Its focus areas include Life Sciences, Gastroenterology, In Vitro Diagnostic Tests and Gastrointestinal Cancer. Its competitors include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.

Company details

Ilico Genetics was founded in 2020 in Bethlehem, United States, within the biotechnology sector. Diagnostic tests for gastric cancer are developed, focusing on molecular analysis of methylated DNA obtained from blood samples. Tumors or lesions in the stomach are detected through this non-invasive method. Operations center on advancing early detection technologies for oncology applications in the diagnostic industry.

Key Metrics
  • Total Equity Funding
    $457.74K (USD)

    in 1 rounds

  • Latest Funding Round
    $457.74K (USD), Seed

    Oct 2023

Products & Services of Ilico Genetics

Ilico Genetics offers a comprehensive portfolio of products and services, including Stomach Cancer Screening Test.

Stomach Cancer Screening Test
Diagnostic Test

Blood test to detect early-stage gastric cancer before symptoms.

Apps and channels of Ilico Genetics

its YouTube channel Ilico Genetics has 1 subscribers.

Ilico Genetics
YouTube 1 subscribers Health & Fitness
Open channel

Funding Insights of Ilico Genetics

Ilico Genetics has successfully raised a total of $457.74K through 1 strategic funding round. The most recent funding activity was a Seed round of $457.74 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $457,735
  • Total Rounds 1
  • Last Round Seed β€” $457,735
  • First Round $457,735

    (Oct 2023)

All 1 funding rounds of Ilico Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2023$457,735Seed––
–

People of Ilico Genetics

5 people are tracked at Ilico Genetics (5 in leadership).

NameRoleGroup
Fernando Alarcon Hardy
Co-Founder & CEOLeadership
Alejandro Corvalan
Co-FounderLeadership
Maria Maturana
Co-FounderLeadership
Maria Jose Maturana Rojas
Co-founder & COOLeadership
Fernando Alarcon
Co-founder & CEOLeadership
Premium access

Complete people profiles for Ilico Genetics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Ilico Genetics

2 dated milestones of Ilico Genetics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ilico Genetics is founded.
  2. Funding First funding round of $458K.

Competitors of Ilico Genetics

Ilico Genetics has 3 listed competitors in our database. They include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
intimabioscience.com2014New York, United States
Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing.
tlrtx.com2022Wilmington, United States
Develops innovative therapeutics for treating myelodysplastic syndrome and gastric cancer.
kupfferbio.com2019Burlingame, United States
Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers.
Premium access

Detailed competitors of Ilico Genetics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Gastroenterology

3 companies that operate in the same segment as Ilico Genetics (Gastroenterology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
1998Cambridge, Massachusetts, United StatesUSD 206.25 MUSD 296.15 M253
Sacral neuromodulation devices are developed for urinary and bowel control.
2013Irvine, California, United StatesUSD 143.47 M
Provider of a deep learning platform for detecting circulating cancer-related markers
2014United StatesUSD 1.35 B411
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Ilico Genetics

Ilico Genetics was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Ilico Genetics is headquartered in Bethlehem, United States.

Fernando Alarcon Hardy is the CEO of Ilico Genetics, as recorded in our data. They have also founded this company.

Ilico Genetics is a funded company, having raised a total of $457.74K across 1 funding round to date. The company's 1st funding round was a Seed of $457.74K, raised on Oct 2023.

Ilico Genetics was founded in 2020 in Bethlehem, United States, within the biotechnology sector. Diagnostic tests for gastric cancer are developed, focusing on molecular analysis of methylated DNA obtained from blood samples. Tumors or lesions in the stomach are detected through this non-invasive method. Operations center on advancing early detection technologies for oncology applications in the diagnostic industry.

Ilico Genetics's top competitors include Intima Bioscience, TLR Therapeutics and Kupffer Biotherapeutics.

Ilico Genetics offers Stomach Cancer Screening Test.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available